Program
Topotecan
Also written as “topotecan”, “topotecan hydrochloride” and “Topotecan/Docetaxel combination”.
Its studies are mostly in Small Cell Lung Carcinoma · Ovarian Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms, led by 15 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 180 open or running | phase 3since Aug 14, 2002 | Nov 2, 1999 | none ahead |
| Bristol-Myers Squibb | 20 open or running | phase 2since Sep 10, 2005 | Sep 10, 2005 | none ahead |
| AbbVie | 10 open or running | phase 3since Dec 10, 2015 | Dec 10, 2015 | none ahead |
| Advenchen Laboratories | 11 open or running | phase 3since Aug 28, 2015 | Aug 28, 2015 | none ahead |
| ascenta-therapeutics | 10 open or running | phase 2since Nov 7, 2006 | Nov 7, 2006 | none ahead |
| AstraZeneca | 10 open or running | phase 2since Apr 10, 2001 | Apr 10, 2001 | none ahead |
| BioNTech | 11 open or running | phase 2since Jun 3, 2024 | Jun 3, 2024 | Jun 2027phase 2 · NCT06449209 |
| Chong Kun Dang Pharmaceutical | 10 open or running | phase 2since Mar 6, 2012 | Mar 6, 2012 | none ahead |
| Gilead Sciences | 11 open or running | phase 3since Jan 24, 2025 | Jan 24, 2025 | Oct 2029phase 3 · NCT06801834 |
| Hoffmann-La Roche | 10 open or running | phase 3since Sep 11, 2012 | Sep 11, 2012 | none ahead |
| Johnson & Johnson | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Novartis | 10 open or running | phase 1since Jun 17, 2022 | Jun 17, 2022 | none ahead |
| Pfizer | 10 open or running | phase 2since Oct 9, 2018 | Oct 9, 2018 | none ahead |
| Sichuan Biokin Pharmaceutical | 11 open or running | phase 3since Jul 8, 2024 | Jul 8, 2024 | Dec 2026phase 3 · NCT06500026 |
| SynerGene Therapeutics | 10 open or running | phase 1since Dec 18, 2014 | Dec 18, 2014 | none ahead |
Also a collaborator on its studies: Eisai, baili-bio-chengdu-pharmaceutical-co-ltd and prologue-research-international.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since Nov 1, 1999.
- Jun 16, 2008Phase 2 study in Small Cell Lung CarcinomaGlaxoSmithKline · NCT00698516 · 50 enrolled · United States
- Aug 11, 2008Phase 1 study in Solid TumoursGlaxoSmithKline · NCT00732420 · 68 enrolled · United States, Netherlands
- Mar 6, 2012Chong Kun Dang Pharmaceutical's first study: phase 2 study in Carcinoma, Ovarian EpithelialNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT01630018 · 141 enrolled · Korea, Republic of
- Sep 11, 2012Hoffmann-La Roche's first study: phase 3 study in Ovarian NeoplasmsNew to Hoffmann-La RocheHoffmann-La Roche · NCT01684878 · 208 enrolled · Austria, Belgium, Denmark and more
- Dec 18, 2014SynerGene Therapeutics's first study: phase 1 study in NeoplasmsNew to SynerGene TherapeuticsSynerGene Therapeutics · NCT02354547 · 18 enrolled · United States
- Aug 28, 2015Advenchen Laboratories's first study: phase 3 study in Endometrial NeoplasmsNew to Advenchen LaboratoriesAdvenchen Laboratories · NCT02584478 · 294 enrolled · United States, China, Italy and more
- Dec 10, 2015AbbVie's first study: phase 3 study in Carcinoma, Ovarian EpithelialNew to AbbVieAbbVie · NCT02631876 · 366 enrolled · United States, Belgium, Bosnia and Herzegovina and more
- Oct 9, 2018Pfizer's first study: phase 2 study in Sarcoma, EwingNew to PfizerPfizer · NCT03709680 · 128 enrolled · United States, Brazil, Canada and more
- Jun 17, 2022Novartis's first study: phase 1 study in NeuroblastomaNew to NovartisNovartis · NCT05429502 · 12 enrolled · United States, Germany, Italy and more
- Nov 4, 2022Phase 2 study in Ovarian NeoplasmsBristol-Myers Squibb · NCT05613088 · 106 enrolled · United States, Australia, Belgium and more
- Jun 3, 2024BioNTech's first study: phase 2 study in Small Cell Lung CarcinomaNew to BioNTechBioNTech · NCT06449209 · 110 enrolled · United States, Australia, South Korea and more
- Jul 8, 2024Sichuan Biokin Pharmaceutical's first study: phase 3 study in Small Cell Lung CarcinomaNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT06500026 · 722 enrolled · China
- Jan 24, 2025Gilead Sciences's first study: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)New to Gilead SciencesGilead Sciences · NCT06801834 · 695 planned · United States, Argentina, Australia and more
- Oct 28, 2026Phase 2 study terminatedStudy stoppedNCT05613088 · “Business objectives have changed.”
Ahead
- Dec 2026Primary completion: phase 3 study in Small Cell Lung CarcinomaSichuan Biokin Pharmaceutical · NCT06500026
- Jun 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaBioNTech · NCT06449209
- Oct 2029Primary completion: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)Gilead Sciences · NCT06801834
TargetBeta
“DNA topoisomerase I inhibitor”ChEMBL 37, by rule
Other programs on TOP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| irinotecan sucrosofaterule | CSPC Pharmaceutical Group | phase 3 | 20 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more | 3 | Recruiting | Gilead Sciences | Oct 2029 | 695 |
| NCT06500026Small Cell Lung Carcinoma · China | 3 | Active, not recruiting | Sichuan Biokin Pharmaceutical | Dec 2026 | 722 |
| NCT06449209Small Cell Lung Carcinoma · United States, Australia, South Korea and more | 2 | Active, not recruiting | BioNTech | Jun 2027 | 110 |
| NCT05613088Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Terminated | Bristol-Myers Squibb | Jun 17, 2024 | 106 |
| NCT05429502Neuroblastoma · United States, Germany, Italy and more | 1 | Terminated | Novartis | Feb 26, 2025 | 12 |
| NCT03709680Sarcoma, Ewing · United States, Brazil, Canada and more | 2 | Completed | Pfizer | Aug 26, 2024 | 128 |
| NCT02631876Carcinoma, Ovarian Epithelial · United States, Belgium, Bosnia and Herzegovina and more | 3 | Completed | AbbVie | Jan 2019 | 366 |
| NCT02584478Endometrial Neoplasms · United States, China, Italy and more | 3 | Active, not recruiting | Advenchen Laboratories | Oct 2024 | 294 |
| NCT02354547Neoplasms · United States | 1 | Suspended | SynerGene Therapeutics | Dec 2027 | 18 |
| NCT01684878Ovarian Neoplasms · Austria, Belgium, Denmark and more | 3 | Completed | Hoffmann-La Roche | Jan 30, 2015 | 208 |
| NCT01630018Carcinoma, Ovarian Epithelial · Korea, Republic of | 2 | Completed | Chong Kun Dang Pharmaceutical | Jun 2014 | 141 |
| NCT00732420Solid Tumours · United States, Netherlands | 1 | Completed | GlaxoSmithKline | Jun 12, 2013 | 68 |
| NCT00698516Small Cell Lung Carcinoma · United States | 2 | Completed | GlaxoSmithKline | May 2010 | 50 |
| NCT00483860Neoplasms · United States, Korea, Republic of, Netherlands | 1 | Completed | GlaxoSmithKline | Feb 6, 2012 | 59 |
| NCT00437073Breast Neoplasms · United States, Austria, Belgium and more | 2 | Terminated | GlaxoSmithKline | Jan 2009 | 22 |
| NCT00397293Small Cell Lung Carcinoma · United States, Russian Federation, Ukraine | 2 | Completed | ascenta-therapeutics | Dec 2008 | 36 |
| NCT00390806Carcinoma, Non-Small-Cell Lung · United States, Canada, Hungary and more | 3 | Completed | GlaxoSmithKline | Jul 2012 | 472 |
| NCT00361803Neoplasms · United States | 1 | Completed | GlaxoSmithKline | Aug 9, 2007 | 15 |
| NCT00320359Small Cell Lung Carcinoma · Austria, Germany | 3 | Completed | GlaxoSmithKline | Feb 2007 | 700 |
| NCT00276276Small Cell Lung Carcinoma · Bulgaria, Hungary, Netherlands and more | 3 | Completed | GlaxoSmithKline | 141 | |
| NCT00267488Endometrial Neoplasms · United States, Canada, Hungary | 2 | Completed | GlaxoSmithKline | Dec 2007 | 70 |
| NCT00259935Small Cell Lung Carcinoma · United States, Netherlands | 1 | Completed | GlaxoSmithKline | Jul 5, 2007 | 107 |
| NCT00179712Ovarian Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | 60 | |
| NCT00158886Carcinoma, Renal Cell · United States | 1 | Terminated | GlaxoSmithKline | Aug 11, 2006 | 26 |
| NCT00065182Carcinoma, Non-Small-Cell Lung · United States, Canada, Poland | 2 | Completed | GlaxoSmithKline | Aug 30, 2007 | 399 |
| NCT00061308Ovarian Neoplasms · United States, Canada | 2 | Completed | GlaxoSmithKline | Sep 2004 | 75 |
| NCT00049998Carcinoma, Non-Small-Cell Lung · Australia, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | Apr 2004 | 760 |
| NCT00046111Small Cell Lung Carcinoma · United States, Canada | 1 | Completed | GlaxoSmithKline | Apr 2004 | 1 |
| NCT00043927Small Cell Lung Carcinoma · United States, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | Jan 2004 | 760 |
| NCT00043862Small Cell Lung Carcinoma · United States | 2 | Completed | GlaxoSmithKline | Nov 2005 | 60 |
| NCT00014690Fallopian Tube Neoplasms · United States | 2 | Completed | AstraZeneca | ||
| NCT00002395HIV Infections · United States | 2 | Completed | GlaxoSmithKline | 54 | |
| NCT00003827Leukemia · United States | 2 | UNKNOWN | Johnson & Johnson | 25 |
How it is read
Names in the registry
- “Topotecan”, 15 entries
- “topotecan”, 11 entries
- “topotecan hydrochloride”, 2 entries
- “Topotecan/Docetaxel combination”, 1 entry
- “Topotecan (Chemotherapy)”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 11 studies
- Ovarian Neoplasms, 4 studies
- Neoplasms, 3 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Endometrial Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.